Oppenheimer set a $13.00 price objective on KemPharm (NASDAQ:KMPH) in a report published on Sunday. The firm currently has a buy rating on the specialty pharmaceutical company’s stock. Oppenheimer also issued estimates for KemPharm’s Q1 2018 earnings at ($0.65) EPS, Q2 2018 earnings at ($0.65) EPS, Q3 2018 earnings at ($0.39) EPS, Q4 2018 earnings at ($0.30) EPS, FY2018 earnings at ($1.81) EPS, FY2019 earnings at ($1.66) EPS, FY2020 earnings at ($2.03) EPS, FY2021 earnings at ($1.42) EPS and FY2022 earnings at ($0.81) EPS.
A number of other equities research analysts have also issued reports on the company. ValuEngine upgraded KemPharm from a strong sell rating to a sell rating in a research note on Sunday, December 31st. Royal Bank of Canada set a $9.00 price target on KemPharm and gave the stock a buy rating in a research note on Tuesday, January 16th. Canaccord Genuity set a $11.00 price target on KemPharm and gave the stock a buy rating in a research note on Friday, February 23rd. Finally, Zacks Investment Research upgraded KemPharm from a hold rating to a buy rating and set a $4.25 price target for the company in a research note on Wednesday, November 15th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the stock. KemPharm currently has a consensus rating of Buy and a consensus price target of $9.15.
Shares of KemPharm (NASDAQ:KMPH) opened at $5.85 on Friday. KemPharm has a 12 month low of $2.45 and a 12 month high of $7.15. The company has a quick ratio of 7.56, a current ratio of 7.56 and a debt-to-equity ratio of -1.92. The stock has a market capitalization of $85.75 and a price-to-earnings ratio of -2.00.
KemPharm Company Profile
KemPharm, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in the discovery and development of prodrugs. The Company uses its Ligand Activated Therapy (LAT) platform technology to create prodrugs. The Company’s product candidate, KP201/APAP, consists of KP201, its prodrug of hydrocodone, which is combined with acetaminophen (APAP).
Receive News & Ratings for KemPharm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for KemPharm and related companies with MarketBeat.com's FREE daily email newsletter.